Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

131.76 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗

August 05, 2026

XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.

Via The Motley Fool

Topics ETFs

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

August 05, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q2 CY2026, with sales up 10.2% year on year to $7.80 billio...

Via StockStory

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

August 04, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance ↗

August 04, 2026

Via Chartmill

Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗

July 24, 2026

Via Chartmill

Gilead Sciences Q2 Earnings Call Highlights ↗

August 04, 2026

Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology...

Via MarketBeat

Topics Earnings

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

August 04, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on yea...

Via StockStory

Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up ↗

August 04, 2026

Gilead Sciences narrowly beat sales expectations for HIV PrEP drug, Yeztugo.

Via Investor's Business Daily

SpaceX Could Swing $204 Billion After Earnings ↗

August 03, 2026

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Via Benzinga

Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity ↗

August 03, 2026

Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral...

Via MarketBeat

Compugen Q2 Earnings Call Highlights ↗

August 03, 2026

Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash...

Via MarketBeat

Topics Earnings

Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗

August 03, 2026

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings...

Via Benzinga

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

August 02, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here’s what to expect. Gilead Sciences be...

Via StockStory

Topics Artificial Intelligence

2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges

July 31, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial ↗

July 28, 2026

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.

Via Benzinga

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗

July 28, 2026

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

Via The Motley Fool

Topics ETFs

Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034 ↗

July 27, 2026

According to a new report from Intel Market Research, the global Prophylactic HIV Drug Market was valued at USD 3.45 billion in 2025 and is projected to re

Via Talk Markets

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

July 24, 2026

From Gilead Sciences, Inc.

Via Business Wire

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗

July 23, 2026

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

Via The Motley Fool

Topics ETFs

Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗

July 22, 2026

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

Via The Motley Fool

Topics ETFs

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill ↗

July 21, 2026

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.

Via Benzinga

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

3 Market-Beating Stocks with Solid Fundamentals

July 21, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Topics Energy

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

July 20, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market...

Via Benzinga

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Via The Motley Fool

Topics ETFs

Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. ↗

July 17, 2026

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Via Investor's Business Daily

Topics Intellectual Property

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings ↗

July 16, 2026

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.